Guardant360® CDx provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing.
Lung Cancer Brochure
Test patients newly diagnosed with NSCLC with Guardant360® to help accelerate time to complete biomarker results
The answers your doctor needs to build your treatment plan are in your blood.
You have questions. A simple blood test may have answers.
Clinical cancer research
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer
Clinical lung cancer
Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
Journal of Clinical Oncology
Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer